40 results about "Viral entry" patented technology

The invention relates to an algin sulfate (PMGS) patch as well as a preparation method and application thereof, and belongs to the technical field of medicines. According to the application, the fucoidan polysaccharide sulfate (PMGS) is used as a main raw material of the microneedle for the first time, the needle tip is completely composed of PMGS, the PMGS plays a role in medicine and adjuvant integration, on one hand, the PMGS is used as a needle tip matrix to provide enough mechanical strength to pierce warts and surrounding skin and is more suitable for related warts with obvious skin thickening, and on the other hand, the PMGS is diffused and released at the position where viruses are located, so that the effect of preventing and treating warts is achieved. The skin wart treatment effect is achieved by preventing virus from entering and enhancing skin immunity, compared with a previous authorized patent scheme, the problems that PMGS as macromolecular polysaccharide enters the skin and is insufficient in absorption are solved in a microneedle mode, PMGS can be directly delivered to basal layer cells where HPV is located, and fixed-point drug delivery is achieved.

This invention relates to an anti-swine pseudorabies virus (PRV) preparation and the application of Rehmannia glutinosa polysaccharide in its preparation, belonging to the field of biopharmaceutical technology. This invention provides an anti-swine pseudorabies virus (PRV) preparation comprising Rehmannia glutinosa polysaccharide. It also provides the application of Rehmannia glutinosa polysaccharide in the preparation of an anti-PRV preparation for the prevention and / or treatment of swine pseudorabies. This invention utilizes Rehmannia glutinosa polysaccharide to prevent infection by the PRV variant XJ5 by reducing intracellular oxidative stress levels; it also resists viral infection by affecting viral adsorption. Furthermore, when the concentration of Rehmannia glutinosa polysaccharide is between 50 and 400 μg / mL, it can also affect viral entry and replication, and has no cytotoxicity to PK-15 cells.

Disclosed herein are compositions that block entry of enveloped viruses into cells, polynucleotides encoding the same, pharmaceutical compositions, and methods of treating viral infections in subjects using the disclosed compositions. Also disclosed are compositions that make a cell susceptible to viral infection, polynucleotides encoding the same and methods of making a cell susceptible to viral infection, methods of targeting an oncolytic virus to a cell, and methods of inducing cell-cell fusion.

The present invention provides a mammalian cell line that has been genetically engineered to make it resistant to viral entry and / or replication; and provides a method for using the cell line to reduce or prevent viral contamination of a bioproduction system.

The utility model provides an epidemic prevention safeguard station and an epidemic prevention fattening yard, the epidemic prevention safeguard station comprises a three-section type dressing station and a disinfection station, the three-section type dressing station comprises two dressing rooms and a bath room, and personnel unidirectionally circulate in the three-section type dressing station; the disinfecting and killing station comprises a first buffer room, a wet type treatment room, a dry type treatment room and a second buffer room, the dry type treatment room and the wet type treatment room are located in the middle of the disinfecting and killing station, the first buffer room and the second buffer room are located at the two ends of the disinfecting and killing station respectively, and materials and vehicles unidirectionally circulate in the disinfecting and killing station; the wet-type treatment room comprises soaking equipment for soaking and disinfecting the materials, and the dry-type treatment room comprises drying equipment for drying the materials and further comprises irradiation equipment for irradiating and disinfecting the materials and the vehicles. According to the utility model, personnel, materials and vehicles are controlled, so that the possibility that germs and viruses enter the epidemic prevention fattening field is reduced, the occurrence and transmission of pig diseases are prevented, and the economic benefit of pig raising is improved.

The application relates to the field of biological medicine, and particularly relates to application of Navitoclax (ABT263) in preparation of a broad-spectrum antiviral inhibitor. The application of the compound Navitoclax (ABT263), an analogue or a salt thereof shown in formula (I) in preparation of a broad-spectrum antiviral inhibitor. It is found in the application that the compound has broad-spectrum antiviral activity, including but not limited to SARS-CoV-2, SARS-CoV, MERS-CoV, the compound can act on the virus entry stage, and the virus is resisted outside the target cell. In addition, the compound has a high selection index (CC50 / IC50) for different viruses, and has considerable safety. The application provides a broad-spectrum antiviral small-molecule compound, which has the advantages of simple preparation method, low cost, easy transportation and storage, high safety and good activity, and has a broad prospect in the fields of biological medicine and response to new emerging infectious diseases.

This disclosure relates to methods of treating a coronavirus infection or other microbial infection comprising administering an effective amount of a plant extract, or compound, or combination of compounds derived therefrom to a subject in need thereof. In certain embodiments, the plant extract is obtained by a process of contacting a segment of a plant a with a solvent providing an extract as reported herein. In certain embodiments, this disclosure contemplates pharmaceutical compositions comprising extracts and components contained therein for use in methods of treating viral or other microbial infections.

A robust human cell culture model permissive to both SARS-CoV-2 variants and MERS-CoV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-CoV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-CoV-2 spike protein. By contrast, MERS-CoV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549- ACE2plusC3 cells (ACE2+ / TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 ("ACE2plusC3D4") are highly susceptible to MERS-CoV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.

The present invention relates to the treatment of inflammatory diseases. Here, the inventors analyzed the immune activation triggered by HRV16 in macrophages to elucidate the cellular pathways involved in ARL5b upregulation. They demonstrated that HRV16 does not replicate in macrophages but induces interferon and pro-inflammatory responses. Conversely, in HeLa OHIO cells where the virus replicates, no induction of immune responses is observed. They identify the ICAM1-PKR-ATF2 axis as the primary regulator of HRV16-mediated ARL5b induction in macrophages. By contrast, HRV16-mediated ARL5b decrease in HeLa OHIO is dependent on ICAM-1 / viral entry in the cells but not on PKR signalling. Finally, ARL5b is regulated at the epigenetic level in both HeLa OHIO and human macrophages. An increase in the repressive mark H3K27Me3 is observed in HeLa OHIO, while the activating mark H3K27Ac is increased on the ARL5b promoter in human macrophages. Thus, the invention relates to relates to an inhibitor of the ICAM1 / PKR / ATF2 signalling pathway for use in the improvement of phagocytosis in a subject in need thereof.

To provide a mask capable of: 100% completely preventing droplet infection of novel coronavirus in particular, including to the eyes; allowing wearers to have clear conversation, preventing a transparent plate and glasses from fogging; being usable by women without ruining makeup, being usable over a long period of time; etc.SOLUTION: A mask dedicated to novel coronavirus, is designed to enhance rigidity by bending a flat transparent plate to improve temperature and humidity, prevents virus entry by increasing internal temperature and atmospheric pressure humidity, completely blocks virus droplets from reaching the eyes, nose, and mouth without touching the eyes, nose, and mouth, expels exhaled air to prevent the transparent plate and glasses from fogging, allows wearers to have clear conversation, keeps women's makeup from coming off, can be put in a pocket, allows eating, doubles as an eye mask, is a world's first so-called face shield, and has a highest performance and widest range of uses.SELECTED DRAWING: Figure 4

The invention relates to anti-viral compounds suitable for use in blocking virus entry into cells, and methods of blocking virus entry into cells by associating the cells with the anti-viral compounds. The associating may occur in vitro, or in vivo in a subject through administration of the anti-viral compounds to the subject. The invention also relates to methods of treating or preventing a viral infection in a subject by administering to the subject at least one anti-viral compound. The subject may be a human being suffering from or vulnerable to the viral infection. The virus may include a coronavirus, such as severe acute respiratory syndrome-related coronavirus 2 (SARS-COV-2).

This invention discloses a fermented traditional Chinese medicine preparation for treating porcine epidemic diarrhea virus infection and its application. This fermented traditional Chinese medicine preparation is obtained by fermenting dandelion, isatis root, alisma, kudzu root, scutellaria, licorice, and hawthorn using a probiotic mother liquor. The probiotic mother liquor contains *Lactobacillus rhamnoides*, *Bacillus subtilis*, *Lactobacillus plantarum*, and *Bacillus coagulans*. The preparation method of this fermented traditional Chinese medicine preparation includes the following steps: (1) mixing the herbs, decocting, filtering, and sterilizing to obtain a mixed herbal liquid; (2) adding the probiotic mother liquor to the mixed herbal liquid for fermentation to obtain the fermented traditional Chinese medicine liquid. This fermented traditional Chinese medicine preparation can exert its anti-porcine epidemic diarrhea virus effect in vitro by preventing the virus from entering cells, inhibiting viral replication, and directly killing the virus. It has a significant preventive and therapeutic effect on diseases caused by this virus, is easy to prepare, can be mass-produced, and is beneficial to improving the economic benefits of pig farms.

The invention relates to the technical field of gene engineering, in particular to an avian infectious bronchitis virus system based on double reporter genes and application thereof. According to the avian infectious bronchitis virus system based on the double reporter genes, real-time monitoring of IBV infection and replication can be achieved, the detection sensitivity and specificity are improved, meanwhile, experimental operation is simplified, and cost is reduced. The system can be used for various applications including but not limited to virus susceptible cell testing, virus entry mechanism research, antiviral drug screening, vaccine and neutralizing antibody effect evaluation, virus intrusion inhibitor evaluation and influence research of virus variation on infectivity. The system and the method provided by the invention provide a new tool for research and prevention and control of IBV and other enveloped viruses, and have important scientific and practical application values.

The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a Chinese medicine composition and its application. A Chinese medicine composition, characterized in that it is composed of an ephedra extract, a scutellaria extract and a liquorice extract. The present invention finds that the Chinese medicine composition can synergistically inhibit the invasion of SARS-CoV-2 pseudovirus into human epithelial cells and synergistically inhibit the production of inflammatory factors by macrophages. By preventing the virus from entering cells; preventing the virus from replicating in cells; inhibiting body inflammation; lowering body temperature; relieving cough; resolving phlegm, increasing the amount of airway secretions in the body, etc., it prevents and treats viral respiratory infections and improves related clinical symptoms. According to the prior art, ephedra, scutellaria or liquorice alone cannot effectively inhibit SARS-CoV-2. Based on this discovery, the present invention uses the Chinese medicine composition to prepare a drug for preventing and / or treating viral infections.

The present disclosure relates to a C-based single domain antibody that neutralizes respiratory syncytial virus (RSV) and its application thereof. The C-based single domain antibody of the present disclosure is a neutralizing antibody against RSV F protein, can inhibit the viral entry into host cells, and can be used for the prevention, treatment and diagnosis of RSV, as well as for further studying the mechanism of RSV infection. The C-based single domain antibody has a smaller molecular weight, better tissue permeability and the ability to bind to antigenic epitope with steric hindrance effect; it can be expressed in multiple expression systems, including prokaryotic, yeast, and mammalian cells. The C-based single domain antibody has a low production cost and a short production cycle; it has a wide range of administration routes and can be administered through nasal drops, nasal spray, spray, aerosol inhalation, intramuscular injection, intravenous injection, subcutaneous injection, etc.

This invention discloses a method for manufacturing a negative ion device for preventing and treating airborne viral infections. Specifically, water is added to tourmaline pebbles to moisten them, but not completely immerse them, and additional air pressure is applied to the surface of the wet tourmaline pebbles. The pressure of the tourmaline is used to generate a pressure-electric electrode that is far greater than the spontaneous polarization effect, ionizing surrounding water molecules to produce a large number of hydroxide and hydrogen ions. Hydrogen ions have a weaker electron-capturing ability compared to oxygen molecules and are the lightest substance, so they disperse immediately after being blown out by the fan, resulting in a very low content in the environment. After the hydroxide ions donate electrons, water and oxygen are produced, and the electrons that donate them combine with oxygen molecules blown in by the fan and oxygen molecules produced by their own reactions to form intrinsic negative ions by Brownian motion. Using these negative ions obtained through the Green method, it is possible to promote the decomposition of VOCs, condense and settle PM2.5, aerosols, bacteria, viruses, pollen, etc., inhibit or kill bacteria, change or reverse the polarity of the potential inside and outside the viral capsid, break down the viral spike, rapidly inactivate viruses, and prevent viruses from entering human cells by blocking electrostatic attraction between the viral receptor binding region and the cell membrane receptor. At the same time, it has other health and therapeutic effects such as alleviating respiratory allergies, improving respiratory and circulatory functions, aiding sleep, preventing fatigue, antioxidant, removing free radicals in the body, increasing the body's repair capacity, and enhancing immunity. It can also generate and replenish diffused oxygen and perform mist-free humidification.

The invention relates to an application of torreya grandis aril volatile oil in preparation of a medicine for resisting porcine epidemic diarrhea virus. The torreya grandis aril volatile oil is volatile oil extracted from torreya grandis' Merrillii 'Hu aril of a torreya plant of taxus chinensis family. Researches show that the torreya grandis aril volatile oil can effectively and directly kill viruses, prevent the viruses from entering cells, inhibit the viruses from being copied in the cells and play a role in resisting the porcine epidemic diarrhea viruses, and can be applied to preparation of the medicines for resisting the porcine epidemic diarrhea viruses. The torreya grandis aril volatile oil is rich and cheap in raw materials, simple in preparation process and low in cost, and has good development and application prospects.

Provided herein are, inter alia, peptides capable of binding viral proteins and thereby preventing viral infection, replication and spread (e.g., SARS CoV-2). The conjugates provided herein include a trimerizing domain (e.g., a collagen 18 trimerizing domain) attached through a peptide linker to a viral protein binding domain (e.g., a spike binding domain). The peptides and trimeric compositions provided herein exhibit a unique trimeric symmetry which results in superior binding affinities and low binding entropies providing for desirable compositions inhibit viral entry and treating viral infection.

The present invention relates to the treatment of inflammatory diseases. Here, the inventors analyzed the immune activation triggered by HRV16 in macrophages to elucidate the cellular pathways involved in ARL5b upregulation. They demonstrated that HRV16 does not replicate in macrophages but induces interferon and pro-inflammatory responses. Conversely, in HeLa OHIO cells where the virus replicates, no induction of immune responses is observed. They identify the ICAM1-PKR-ATF2 axis as the primary regulator of HRV16-mediated ARL5b induction in macrophages. By contrast, HRV16-mediated ARL5b decrease in HeLa OHIO is dependent on ICAM-1 / viral entry in the cells but not on PKR signalling. Finally, ARL5b is regulated at the epigenetic level in both HeLa OHIO and human macrophages. An increase in the repressive mark H3K27Me3 is observed in HeLa OHIO, while the activating mark H3K27Ac is increased on the ARL5b promoter in human macrophages. Thus, the invention relates to relates to an inhibitor of the ICAM1 / PKR / ATF2 signalling pathway for use in the improvement of phagocytosis in a subject in need thereof.

A chimeric monoclonal antibody (mAb 77.1) neutralizes measles fusion protein and its cryo-EM structure in complex with MeV F in the prefusion conformation. Vaccine compositions using MeV F protein or its ectodomain are mutated to have stabilized pre-fusion conformation. Vaccine compositions may be varied, targeting other paramyxoviruses; they are mutated forms of paramyxovirus F protein with mutations at specific positions on the protein. Thermostable full-length MeV fusion proteins (FFLs) induce protective immunity and neutralizing antibodies in vivo. Vaccination with the FFL induces neutralization titer higher than with live vaccine, providing robust humoral response, likely protective also for individuals with impaired cellular immunity. The 8 specific mAbs, alone or combined with mAb 77, neutralize post fusion transition of MeV fusion protein, interrupting the F refolding process and preventing conformational changes required for membrane fusion and viral entry: mAbs G3, F3, E11, 9E1D3, H8, 10H2G3, D9, and Y10F.

The invention discloses application of a radix tetrastigme extract in preparation of a medicine for resisting Crimean-Congo hemorrhagic fever virus, and belongs to the technical field of medicine. The anti-CCHFV effect of the radix tetrastigme extract is evaluated on the cellular level by utilizing a CCHFV virus-like particle system capable of simulating virus endocytosis and transcriptional activity, and the result shows that the radix tetrastigme extract has remarkable antiviral activity, is dose-dependent, and has a good application prospect. The antiviral activity mechanism of the radix tetrastigme extract is related to virus cell entry and virus transcription stages. The radix tetrastigme extract provided by the invention shows the activity of inhibiting the CCHFV, and has a wide prospect of being developed into a medicine for treating human CCHFV infection.

The invention relates to an application of polygonum capitatum or an extract of the polygonum capitatum in preparation of an anti-pseudorabies virus drug. The polygonum capitatum is a dry whole herb or an overground part of polygonum capitatum Poly (Polygonum capitatum Buck.-Ham. Ex D.Don) which is a polygonaceae plant. Researches show that the polygonum capitatum extract can effectively and directly kill viruses, prevent the viruses from entering cells, inhibit the viruses from being copied in the cells and play a role in resisting the pseudorabies viruses, the effect of inhibiting the proliferation of the pseudorabies viruses is remarkably superior to that of an antiviral chemical drug acyclovir, and the polygonum capitatum extract can be applied to preparation of the pseudorabies virus resisting medicine. The polygonum capitatum extract is rich and cheap in raw materials, simple in preparation process and low in cost, and has good development and application prospects.

The present invention discloses an envelope glycoprotein for packaging and transducing NK cell pseudotyped lentiviral vector and its application; the envelope glycoprotein includes an extracellular region, a transmembrane region and a cytoplasmic region; wherein the amino acid sequence or mutant sequence of the extracellular region is as shown in SEQ ID NO:1 or SEQ ID NO:2; the amino acid sequence or mutant sequence of the transmembrane region is as shown in SEQ ID NO:3 or SEQ ID NO:4; the amino acid sequence or mutant sequence of the cytoplasmic region is as shown in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8. The BaEV envelope glycoprotein mutant replaces VSV-G to package lentiviral pseudovirus, which not only maintains a high virus titer of 7.33E+07 TU / mL, but also can effectively identify NK cells and mediate the virus to enter cells, thereby achieving the purpose of efficiently transfecting NK cells.

This invention discloses a chimeric antiviral cross-protective antigen mRNA vaccine, its preparation method, and its application. The vaccine consists of lipid materials encapsulating either a first or second type of mRNA, forming nanolipid nanoparticles containing mRNA fragments. The first type of mRNA is obtained through in vitro transcription using a first DNA template, and the second type of mRNA is obtained through in vitro transcription using a second DNA template. The vaccine of this invention possesses the advantage of multi-antigen comprehensive immunity: each vaccine combines one EEV core surface antigen and one IMV core surface antigen. This chimeric strategy can simultaneously induce highly efficient and specific immunity against both types of viral infection particles, both limiting initial viral entry into cells and effectively clearing free viruses from the circulatory system. It not only stimulates strong humoral immunity but also induces specific cellular immune responses, thereby significantly enhancing the vaccine's broad-spectrum cross-protective efficacy against orthopox, vaccinia virus, and other orthopox viruses.

To provide a mask capable of: 100% completely preventing droplet infection of novel coronavirus in particular, including to the eyes; allowing wearers to have clear conversation, preventing a transparent plate and glasses from fogging; being usable by women without ruining makeup, being usable over a long period of time; etc.SOLUTION: A mask dedicated to novel coronavirus, is designed to enhance rigidity by bending a flat transparent plate to improve temperature and humidity, prevents virus entry by increasing internal temperature and atmospheric pressure humidity, completely blocks virus droplets from reaching the eyes, nose, and mouth without touching the eyes, nose, and mouth, expels exhaled air to prevent the transparent plate and glasses from fogging, allows wearers to have clear conversation, keeps women's makeup from coming off, can be put in a pocket, allows eating, doubles as an eye mask, is a world's first so-called face shield, and has a highest performance and widest range of uses.SELECTED DRAWING: Figure 4

The present application relates to viral entry inhibitors and RNA polymerase inhibitors, pharmaceutical compositions comprising one or more of the same, and combination therapies, as well as methods of making and of using the foregoing in the treatment of certain diseases.

The invention relates to an application of polygonum capitatum or an extract of the polygonum capitatum in preparation of a medicine for resisting porcine epidemic diarrhea virus. The polygonum capitatum is a dry whole herb or an overground part of polygonum capitatum Poly (Polygonum capitatum Buck.-Ham. Ex D.Don) which is a polygonaceae plant. Researches show that the polygonum capitatum extract can effectively and directly kill viruses, prevent the viruses from entering cells, inhibit the viruses from being copied in the cells and play a role in resisting the porcine epidemic diarrhea viruses, and can be applied to preparation of the medicine for resisting the porcine epidemic diarrhea viruses. The polygonum capitatum extract is rich and cheap in raw materials, simple in preparation process and low in cost, and has good development and application prospects.

Provided are a sodium-taurocholate cotransporting polypeptide (NTCP) long-acting inhibitor and the use thereof. In particular, provided is a long-acting polypeptide that can be used as an NTCP inhibitor. The present invention also relates to a preparation method for and the use of the polypeptide, and a pharmaceutical composition containing the polypeptide. The NTCP long-acting inhibitor binds to NTCP so as to competitively inhibit the binding between a hepatitis virus surface protein and NTCP, thereby achieving a viral entry inhibition effect on hepatitis viruses. Therefore, said NTCP long-acting inhibitor can serve as a therapeutic or preventive drug for blocking the entry of hepatitis viruses into cells, a drug for inhibiting hepatitis recurrence and a drug for functionally curing hepatitis, and can also serve as a therapeutic drug for type II diabetes, a therapeutic drug for obesity, and a therapeutic drug for intestinal autoimmune diseases, biliary cirrhosis and atherosclerosis.

The invention discloses a micro-injection method for efficiently infecting an organoid, which specifically comprises the following steps: a) placing the organoid in a culture vessel, and reserving a culture solution around the organoid; b) changing one end of the glass electrode into a thin-opening needle tip shape, then connecting one end of a hose to a microsyringe opening, and connecting the other end of the hose to a non-sharp-opening end of the glass electrode; c) extending a thin-mouthed needle tip of a glass electrode into the virus liquid, pulling a micro-injector to enable the virus to enter the glass electrode, inserting the glass electrode into the organoid under a microscope, and pushing the micro-injector to enable quantitative virus to enter the organoid; and d) adding a culture solution, and culturing in a cell culture box. According to the invention, a micro-injector is combined with a glass electrode to construct a micro-injection device, so that viruses can be accurately and quantitatively injected into the organoids; according to the method, the infection rate is increased, meanwhile, the virus usage amount is reduced, cell damage is reduced, the virus absorption amount is quantitatively controlled, and a more efficient and accurate solution is provided for organoid research and application.

The invention discloses a C-based single domain antibody that neutralizes respiratory syncytial virus (RSV) and its application thereof. The C-based single domain antibody of the present invention is a neutralizing antibody against RSV F protein, can inhibit the viral entry into host cells, and can be used for the prevention, treatment and diagnosis of RSV, as well as for further studying the mechanism of RSV infection. The C-based single domain antibody has a smaller molecular weight, better tissue permeability and the ability to bind to antigenic epitope with steric hindrance effect; it can be expressed in multiple expression systems, including prokaryotic, yeast, and mammalian cells. The C-based single domain antibody has a low production cost and a short production cycle; it has a wide range of administration routes and can be administered through nasal drops, nasal spray, spray, aerosol inhalation, intramuscular injection, intravenous injection, subcutaneous injection, etc.